No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
GOSS Gossamer Bio
- 0.670
- -0.038-5.41%
Close Apr 25 16:00 ET
- 0.690
- +0.020+2.99%
Post 19:52 ET
151.57MMarket Cap-567P/E (TTM)
0.693High0.633Low2.48MVolume0.693Open0.708Pre Close1.64MTurnover1.30%Turnover RatioLossP/E (Static)226.22MShares1.88052wk High2.42P/B128.39MFloat Cap0.45352wk Low--Dividend TTM191.63MShs Float27.150Historical High--Div YieldTTM8.46%Amplitude0.453Historical Low0.658Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersTevogen Bio Holdings (NASDAQ:TVGN) shares rose 51.8% to $1.29 during Thursday's after-market session. The company's market cap stands at $212.3 million. Fresh2 Group (NASDAQ:FRES) stock rose 10
12 Health Care Stocks Moving In Friday's After-Market Session
GainersLongeveron (NASDAQ:LGVN) stock rose 48.6% to $3.27 during Friday's after-market session. The company's market cap stands at $8.2 million. Adial Pharmaceuticals (NASDAQ:ADIL) shares increased by
Gossamer Bio Coverage Assumed by Wedbush at Outperform
Gossamer Bio Coverage Assumed by Wedbush at Outperform
Express News | Wedbush Assumes Gossamer Bio at Outperform, Announces Price Target of $4
Express News | Piper Sandler Maintains Overweight on Gossamer Bio, Maintains $15 Price Target
Buy Rating Affirmed on Gossamer Bio With Promising Seralutinib Prospects in PAH Treatment Landscape
Comments
Update
$Gossamer Bio(GOSS.US$ On March 4, 2024, Gossamer Bio Received Letter Stating That It Has Regained Compliance With Minimum Bid Price Requirement For Continued Listing On Nasdaq
Moomoo 24/7· just
Moomoo 24/7· just
Insiders at Gossamer Bio have shown increased interest in the stock over the past year, suggesting no doubts about the company despite no recent insider transactions. Individual holdings could be larger.
1
So far so good!
$Gossamer Bio(GOSS.US$ Pick up a position here after the crash down yesterday! And here we go back up plus data is due out soon! You know i likes me some bottom buying! hehehe
1
Watching closely!
$Gossamer Bio(GOSS.US$ Expecting to see additional data about phase 2 meeting primary endpoints for SERALUTINIB ( GB002 ) Could be as soon as Tomorrow?
1
Insider transactions at Gossamer Bio hint at optimism. Despite no profits in the past year, considerable insider investments and lack of selling suggest they find value in current stock price.
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg